|Bid||0.00 x 1800|
|Ask||14.93 x 900|
|Day's Range||12.01 - 12.39|
|52 Week Range||10.32 - 29.97|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.14|
Ladies and gentlemen, thank you for standing by, and welcome to the second-quarter 2020 Radius Health earnings conference call. Before we begin, I'd like to remind you with our safe harbor slide that will have some forward-looking statements and include non-GAAP financial measures in our presentation today.
Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Radius Health (NASDAQ:RDUS) rose 1.4% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 21.82% year over year to ($0.67), which beat the estimate of ($0.74).Revenue of $50,113,000 up by 22.10% from the same period last year, which beat the estimate of $48,400,000.Guidance Radius Health hasn't issued any earnings guidance for the time being.Radius Health hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on RDUSTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/whbw94tnRecent Stock Performance 52-week high: $29.9752-week low: $10.32Price action over last quarter: down 17.57%Company Description Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.See more from Benzinga * Earnings Scheduled For August 10, 2020 * Benzinga's Top Upgrades, Downgrades For July 8, 2020 * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.